Table 1.
Descriptive characteristics of the study population.
| Rotterdam Study I‐4 | Rotterdam Study III‐2 | LLS | LLD | 300‐OB | |
|---|---|---|---|---|---|
| N | 2556 | 1377 | 2158 | 1650 | 302 |
| Age (years), mean (sd) | 75.14 (6.08) | 62.68 (5.82) | 59.12 (6.71) | 43.94 (14.15) | 67.05 (5.39) |
| Women, N (%) | 1486 (58.14) | 748 (54.32) | 1208 (55.98) | 833 (57.52) | 167 (55.29) |
| Smoking, N (%) | 301 (12.05) | 238 (17.32) | 241 (11.17) | 289 (19.63) | 26 (8.63) |
| Diabetes, N (%) | 346 (13.61) | 123 (8.94) | 90 (4.17) | 28 (1.7) | 37 (12.25) |
| Hypertension, N (%) | 2182 (85.60) | 752 (54.77) | 159 (7.37) | 321 (19.47%) | 175 (57.94) |
| LDLC (mmol/L), mean (sd) | 1.63 (0.44) | 1.76 (0.51) | 1.60 (0.47) | 3.14 (0.91) | 4.13 (0.96) |
| HDLC (mmol/L), mean (sd) | 1.40 (0.28) | 1.37 (0.35) | 1.49 (0.33) | 1.52 (0.40) | 1.33 (0.31) |
| Serum triglycerides (mmol/L), mean (sd) | 1.38 (0.57) | 1.33 (0.62) | 1.55 (0.82) | 1.16 (0.86) | 1.83 (1.02) |
| Lipid‐lowering medication, N (%) | 583 (22.90) | 362 (26.51) | 207 (9.59) | 29 (2.55) | 83 (27.48) |
| BMI (kg/m2), mean (sd) | 27.43 (4.13) | 27.44 (4.50) | 25.43 (3.57) | 25.30 (4.22) | 30.73 (3.48) |
| eGFRaa | 79.41 (13.10) | 95.31 (9.29) | 94.88 (11.60) | 73.13 (12.6) | 80.4 (15.68) |
| Incident cardiovascular disease | 544 | 9 | 85 | 23 | — |
| Follow‐up time cardiovascular disease, mean (years) | 8.62 (3.49) | 2.48 | 10.7 (1.77) | — | — |
| Incident mortality events | 1295 | 37 | 209 | — | — |
| Follow‐up time mortality, mean (years) | 10.15 (3.88) | 2.48 (1.17) | 12.74 (2.22) | — | — |
Abbreviations: 300‐OB, 300‐Obese cohort; BMI, body mass index; eGFR, estimated glomerular filtration rate; HDLC, high‐density lipoproteins; LDLC, cholesterol in low‐density lipoproteins; LLD, LifeLines‐DEEP; LLS, Leiden Longevity Study; sd, standard deviation.
a
eGFR—calculated using the Chronic Kidney Disease Epidemiology Collaboration equation (CKD‐EPI).